Hereditary Breast and Ovarian Cancer Panel
Test code: ON0901
The Blueprint Genetics Hereditary Breast and Ovarian Cancer Panel analyzes 22 genes associated with inherited susceptibility to breast and ovarian cancer.
Breast and ovarian cancers are among the most common cancers in women. While majority of the cancers are sporadic, 5-10% of breast and ovarian cancers are caused by pathogenic germline mutations in cancer susceptibility genes. Inheritance pattern of these genetic cancer susceptibility conditions is predominantly autosomal dominant. The Hereditary Breast and Ovarian Cancer Panel is suited for detecting heritable germline mutations and may not be used for the detection of somatic mutations in tumor tissue. This Panel is part of the Comprehensive Hereditary Cancer Panel.
About Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer syndrome (HBOS) is caused by germline mutations in BRCA1 or BRCA2, and is characterized by an increased risk for breast cancer, ovarian cancer, prostate cancer, and pancreatic cancer. The lifetime risk of developing breast cancer is 40-80% in an individual with a pathogenic BRCA1 or BRCA2 variant. The risk for ovarian cancer is 11-40% and lower for the other cancers. Although HBOS account for a small number of all breast cancers (less than 5%) it accounts for a greater proportion of breast cancer in younger women. After a cancer predisposition germline mutation in BRCA1 or BRCA2 has been identified in a family, family member testing enables identification of mutation carriers in the family. Genetic counselling should be offered for high-risk individuals for surveillance and prevention of primary manifestations. Individuals with the following cancer susceptibility syndromes have also an increased breast cancer risk: Li-Fraumeni syndrome (TP53), Cowden syndrome (PTEN), ataxia-telangiectasia and ataxia-telangiectasia-like disorder (ATM and MRE11A), Fanconi anemia (several genes), hereditary diffuse gastric cancer (CDH1), DICER1 syndrome (DICER1), Nijmegen breakage syndrome and Nijmegen breakage syndrome-like disorder (NBN and RAD50), neurofibromatosis type 1 (NF1), Peutz-Jeghers syndrome (STK11), and Bloom syndrome (BLM). Combined prevalence of the hereditary breast and ovarian cancer is 250:100 000.
Results in 3-4 weeks.
|ATM||Breast cancer, Ataxia-Telangiectasia||AD/AR||455||853|
|BRCA1*||Pancreatic cancer, Breast-ovarian cancer, familial||AD||2207||2054|
|BRCA2||Fanconi anemia, Medulloblastoma, Glioma susceptibility, Pancreatic cancer, Wilms tumor, Breast-ovarian cancer, familial||AD/AR||2514||1791|
|BRIP1||Fanconi anemia, Breast cancer||AD/AR||87||87|
|NBN||Breast cancer, Nijmegen breakage syndrome||AD/AR||57||62|
|NF1*||Watson syndrome, Neurofibromatosis, Neurofibromatosis-Noonan syndrome||AD||261||2607|
|PALB2||Fanconi anemia, Pancreatic cancer, Breast cancer||AD/AR||237||223|
|PPM1D||Hereditary breast cancer||AD||49|
|PTEN*||Bannayan-Riley-Ruvalcaba syndrome, Lhermitte-Duclos syndrome, Cowden syndrome||AD||192||564|
|RAD51C||Fanconi anemia, Breast-ovarian cancer, familial||AD/AR||49||86|
|RAD51D||Ovarian cancer, familial||AD||25||50|
|TP53||Colorectal cancer, Li-Fraumeni syndrome, Ependymoma, intracranial, Choroid plexus papilloma, Breast cancer, familial, Adrenocortical carcinoma, Osteogenic sarcoma, Hepatoblastoma, Non-Hodgkin lymphoma||AD||148||391|
|XRCC2||Hereditary breast cancer||AD/AR||3||13|
- * Some regions of the gene are duplicated in the genome leading to limited sensitivity within the regions. Thus, low-quality variants are filtered out from the duplicated regions and only high-quality variants confirmed by other methods are reported out. Read more.
Gene, refers to HGNC approved gene symbol; Inheritance to inheritance patterns such as autosomal dominant (AD), autosomal recessive (AR) and X-linked (XL); ClinVar, refers to a number of variants in the gene classified as pathogenic or likely pathogenic in ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/); HGMD, refers to a number of variants with possible disease association in the gene listed in Human Gene Mutation Database (HGMD, http://www.hgmd.cf.ac.uk/ac/). The list of associated (gene specific) phenotypes are generated from CDG (http://research.nhgri.nih.gov/CGD/) or Orphanet (http://www.orpha.net/) databases.
Blueprint Genetics offers a comprehensive hereditary breast and ovarian cancer panel that covers classical genes associated with ataxia-telangiectasia, ataxia-telangiectasia variant, ataxia-telangiectasia-like disorder, Bloom syndrome, breast and ovarian cancer, Cowden syndrome, DICER1 syndrome, familial multinodular goiter, Fanconi anemia, hereditary breast and ovarian cancer syndrome, hereditary diffuse gastric cancer, hereditary retinoblastoma, Li-Fraumeni syndrome 1, Li-Fraumeni syndrome 2, neurofibromatosis type 1, Nijmegen breakage syndrome, Nijmegen breakage syndrome-like disorder and Peutz-Jeghers syndrome. The genes are carefully selected based on the existing scientific evidence, our experience and most current mutation databases. Candidate genes are excluded from this first-line diagnostic test. The test does not recognise balanced translocations or complex inversions, and it may not detect low-level mosaicism. The test should not be used for analysis of sequence repeats or for diagnosis of disorders caused by mutations in the mitochondrial DNA.
Please see our latest validation report showing sensitivity and specificity for SNPs and indels, sequencing depth, % of the nucleotides reached at least 15x coverage etc. If the Panel is not present in the report, data will be published when the Panel becomes available for ordering. Analytical validation is a continuous process at Blueprint Genetics. Our mission is to improve the quality of the sequencing process and each modification is followed by our standardized validation process. All the Panels available for ordering have sensitivity and specificity higher than > 0.99 to detect single nucleotide polymorphisms and a high sensitivity for indels ranging 1-19 bp. The diagnostic yield varies substantially depending on the used assay, referring healthcare professional, hospital and country. Blueprint Genetics’ Plus Analysis (Seq+Del/Dup) maximizes the chance to find molecular genetic diagnosis for your patient although Sequence Analysis or Del/Dup Analysis may be cost-effective first line test if your patient’s phenotype is suggestive for a specific mutation profile. Detection limit for Del/Dup analysis varies through the genome from one to six exon Del/Dups depending on exon size, sequencing coverage and sequence content.
The sequencing data generated in our laboratory is analyzed with our proprietary data analysis and annotation pipeline, integrating state-of-the art algorithms and industry-standard software solutions. Incorporation of rigorous quality control steps throughout the workflow of the pipeline ensures the consistency, validity and accuracy of results. The highest relevance in the reported variants is achieved through elimination of false positive findings based on variability data for thousands of publicly available human reference sequences and validation against our in-house curated mutation database as well as the most current and relevant human mutation databases. Reference databases currently used are the 1000 Genomes Project (http://www.1000genomes.org), the NHLBI GO Exome Sequencing Project (ESP; http://evs.gs.washington.edu/EVS), the Exome Aggregation Consortium (ExAC; http://exac.broadinstitute.org), ClinVar database of genotype-phenotype associations (http://www.ncbi.nlm.nih.gov/clinvar) and the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk). The consequence of variants in coding and splice regions are estimated using the following in silico variant prediction tools: SIFT (http://sift.jcvi.org), Polyphen (http://genetics.bwh.harvard.edu/pph2/), and Mutation Taster (http://www.mutationtaster.org).
Through our online ordering and statement reporting system, Nucleus, the customer can access specific details of the analysis of the patient. This includes coverage and quality specifications and other relevant information on the analysis. This represents our mission to build fully transparent diagnostics where the customer gains easy access to crucial details of the analysis process.
In addition to our cutting-edge patented sequencing technology and proprietary bioinformatics pipeline, we also provide the customers with the best-informed clinical report on the market. Clinical interpretation requires fundamental clinical and genetic understanding. At Blueprint Genetics our geneticists and clinicians, who together evaluate the results from the sequence analysis pipeline in the context of phenotype information provided in the requisition form, prepare the clinical statement. Our goal is to provide clinically meaningful statements that are understandable for all medical professionals, even without training in genetics.
Variants reported in the statement are always classified using the Blueprint Genetics Variant Classification Scheme modified from the ACMG guidelines (Richards et al. 2015), which has been developed by evaluating existing literature, databases and with thousands of clinical cases analyzed in our laboratory. Variant classification forms the corner stone of clinical interpretation and following patient management decisions. Our statement also includes allele frequencies in reference populations and in silico predictions. We also provide PubMed IDs to the articles or submission numbers to public databases that have been used in the interpretation of the detected variants. In our conclusion, we summarize all the existing information and provide our rationale for the classification of the variant.
A final component of the analysis is the Sanger confirmation of the variants classified as likely pathogenic or pathogenic. This does not only bring confidence to the results obtained by our NGS solution but establishes the mutation specific test for family members. Sanger sequencing is also used occasionally with other variants reported in the statement. In the case of variant of uncertain significance (VUS) we do not recommend risk stratification based on the genetic finding. Furthermore, in the case VUS we do not recommend use of genetic information in patient management or genetic counseling. For some cases Blueprint Genetics offers a special free of charge service to investigate the role of identified VUS.
We constantly follow genetic literature adapting new relevant information and findings to our diagnostics. Relevant novel discoveries can be rapidly translated and adopted into our diagnostics without delay. These processes ensure that our diagnostic panels and clinical statements remain the most up-to-date on the market.
Full service only
Choose an analysis method
ICD & CPT codes
Commonly used ICD-10 codes when ordering the Hereditary Breast and Ovarian Cancer Panel
|C50||Breast and ovarian cancer|
Accepted sample types
- EDTA blood, min. 1 ml
- Purified DNA, min. 5μg
- Saliva (Oragene DNA OG-500 kit)
Label the sample tube with your patient’s name, date of birth and the date of sample collection.
Note that we do not accept DNA samples isolated from formalin-fixed paraffin-embedded (FFPE) tissue.